Novo Nordisk | NVO - Interest Expense On Debt


Novo Nordisk reported DKK82.1M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
ANI Pharmaceuticals USD 4.73M 711K Sep/2025
Aurora Cannabis CAD 2.22M 442K Sep/2025
Bausch Health Companies USD 412M 53M Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Drreddys Laboratories INR 944M 127M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Merck USD 412M 85M Dec/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Phibro Animal Health USD 8.76M 2.76M Sep/2024
Prestige Brands USD 10.67M 636K Dec/2025
Sanofi EUR -25M 252M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 57M 1000K Dec/2025